StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Down 25.5 %
NASDAQ:BLPH opened at $0.01 on Friday. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The stock’s 50-day moving average price is $0.03 and its 200-day moving average price is $0.04. The stock has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74.
Bellerophon Therapeutics Announces Dividend
The firm also recently announced a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were paid a dividend of $0.019 per share. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- How to Use the MarketBeat Stock Screener
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- The How And Why of Investing in Oil Stocks
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
